Pediatrix Medical Group, Inc. (MD) FY2025 10-K Annual Report
Pediatrix Medical Group, Inc. (MD) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Pediatrix Medical Group, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: provider of neonatal and pediatric healthcare services
- • No new products, services, or segments introduced or emphasized this year
- • No stated strategic shift or changed competitive positioning vs prior year
- • 144 holders of record of common stock as of February 13, 2026; stock price $21.52 per share
- • No dividends declared or paid in 2023-2025; dividend payments limited by credit agreement
Management Discussion & Analysis
- • Revenue details and YoY change not disclosed in provided text
- • Profitability or margin changes not specified in provided text
- • Segment details: 1,350 neonatal physicians, 475 maternal-fetal, 230 pediatric intensive care, 220 hospital-based pediatric, 20 pediatric surgical
- • No cash flow, buybacks, dividends, or capex info given
- • Risks: potential revenue impact from shifts toward government healthcare programs due to economic/demographic changes and rising bad debt from patient payment difficulties
Risk Factors
- • Regulatory/legal risk: potential audit, inquiry, or investigation impact on revenue from government agencies over $1.15B gross receivables and DSO 42.8 days
- • Geopolitical/macro risk: 32% of net revenue concentrated in Texas exposing Pediatrix to regional health policy or economic shifts
- • Operational/supply chain risk: transformation and restructuring expenses $22.3M in 2025 due to shared services position eliminations and revenue cycle transitions
- • Competitive/market disruption risk: practice dispositions reducing net revenue by $99.1M or 4.9% in 2025, affecting market footprint and growth
- • Financial/structural risk: goodwill impairment charge of $150.6M in 2024 reflecting valuation sensitivity to market capitalization and stock price declines
Pediatrix Medical Group, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$1.9B
▼ -4.9% YoY
Net Income
$165M
▲ +266.9% YoY
Operating Margin
10.9%
▲ +1432bp YoY
Net Margin
8.6%
▲ +1356bp YoY
ROE
19.1%
▲ +3205bp YoY
Total Assets
$2.2B
▲ +4.4% YoY
EPS (Diluted)
$1.94
▲ +263.0% YoY
Operating Cash Flow
$271M
▲ +31.2% YoY
Source: XBRL data from Pediatrix Medical Group, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Pediatrix Medical Group, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.